Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Roche inks deal worth up to $600 million for Prothena's Parkinson's drug PRX002; Prothena shares rose about 7.7% in after-market trading following the…
At deal signing, Nature Biotechnology framed Roche's $30M upfront / up to $600M biobucks bet on Prothena as the highest-profile alpha-synuclein wager in…
Roche committed to Phase 3 prasinezumab despite Pasadena and Padova both missing primary endpoints; Prothena has collected $135M of up to $630M deal value…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Roche/Prothena License, Development & Commercialisation agreement for anti-alpha-synuclein mAbs (prasinezumab); $30M upfront + up to $600M milestones + US profit share + ex-US royalties.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Prothena Corporation plc (this deal) | 2013 | $630M | — |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2013 deals · Roche Holding AG deals · Neurology deals